Press Releases
Newsletters
AGT Newsletter Volume 10
VOLUME 10 September 2020 Newsletter We’ve achieved a number of significant milestones this quarter, including the Food and Drug Administration (FDA) clearance to begin Phase 1 of our HIV cure program. The excit...
AGT Newsletter Volume 9
VOLUME 9 May 2020 Newsletter FDA Progress The Path to the Clinic For the HIV Cure This month, AGT saw tremendous progress with the FDA. FDA time and attention to our project has seemed to increase while agency...
Happy New Year! AGT Newsletter – 2020 Edition
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about potential milestones and significant inflection points ...
AGT Newsletter Volume 8
Featured Stories AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial...
Latest Videos
Published Articles
Latest From The Blog
Join Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
Latest AGT Tweets
Wear a conversation for change.
Support cure research by getting AGT gear designed by our own @NormanRogers
https://t.co/DiarOBg5zo
#Pipettepirate #genejockey
With our patents and process in place, we are finally able to share details of our #HIV cure program in a peer-reviewed article in @MolTherapy 👉 https://t.co/I56s6rA1Gp
About our HIV Program https://t.co/JkgdBZ9VC5
#croi2021 #GeneTherapy #CellTherapy #Biotech https://t.co/jgaYn4FNwe
AGT's purpose is to help those who have suffered throughout the world, who have yet to see a cure. This company intends to change that outcome for the better. AGT is modifying cells in 3 ways to stop, turn off, and kill the virus.
Read: https://t.co/QtEPbkCJ3K #HIV
